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Abstract
AIM: To evaluate the completion rate and diagnostic 
yield of the PillCam SB2-ex in comparison to the 
PillCam SB2.
METHODS: Two hundred cases using the 8-h PillCam 
SB2 were retrospectively compared to 200 cases using 
the 12 h PillCam SB2-ex at a tertiary academic center. 
Endoscopically placed capsules were excluded from the 
study. Demographic information, indications for capsule 
endoscopy, capsule type, study length, completion of 
exam, clinically significant findings, timestamp of most 
distant finding, and significant findings beyond 8 h 
were recorded.
RESULTS: The 8 and 12 h capsule groups were well 
matched respectively for both age (70.90 ± 14.19 
vs  71.93 ± 13.80, P  = 0.46) and gender (45.5% vs  
48% male, P  = 0.69). The most common indications 
for the procedure in both groups were anemia and 
obscure gastrointestinal bleeding. PillCam SB2-ex had 
a significantly higher completion rate than PillCam SB2 
(88% vs  79.5%, P  = 0.03). Overall, the diagnostic 
yield was greater for the 8 h capsule (48.5% for SB2 
vs  35% for SB2-ex, P  = 0.01). In 4/70 (5.7%) of 
abnormal SB2-ex exams the clinically significant finding 
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was noted in the small bowel beyond the 8 h mark.
CONCLUSION: In our study, we found the PillCam 
SB2-ex to have a significantly increased completion 
rate, though without any improvement in diagnostic 
yield compared to the PillCam SB2.
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Core tip: The PillCam SB2-ex and the PillCam SB2 have 
the same size and specifications, except the PillCam 
SB2-ec offers 12 h of operation, 4 more hours than 
the original PillCam SB2. There has been no evaluation 
regarding the completion rate and diagnostic yield 
between these two capsules. We examined 200 
cases using the 8-h PillCam SB2 and compared it to 
200 cases using the 12 h PillCam SB2-ex. We found 
the PillCam SB2-ex to have a significantly increased 
completion rate, though without any improvement in 
the diagnostic yield compared to the PillCam SB2.
Rahman M, Akerman S, DeVito B, Miller L, Akerman M, Sultan 
K. Comparison of the diagnostic yield and outcomes between 
standard 8 h capsule endoscopy and the new 12 h capsule 
endoscopy for investigating small bowel pathology. World J 
Gastroenterol 2015; 21(18): 5542-5547  Available from: URL: 
http://www.wjgnet.com/1007-9327/full/v21/i18/5542.htm  DOI: 
http://dx.doi.org/10.3748/wjg.v21.i18.5542
INTRODUCTION
Capsule endoscopy has proven to be an effective 
method to investigate small bowel pathology including 
Crohn’s disease, unexplained abdominal pain, diarrhea, 
and obscure gastrointestinal (GI) bleeding[1,2]. Of 
these indications, capsule endoscopy has become 
the first-line option for evaluation of obscure GI 
bleeding which is defined as “overt bleeding and/or 
anemia with a negative endoscopic workup including 
complete colonoscopy and gastroscopy”[3]. The PillCam 
SB (previously known as the M2A; Given Imaging, 
Yokneam, Israel) which was introduced in 2001[1,4,5] 
began the era of capsule endoscopy for day to day 
clinical use[3,4].
The MiroCam (IntroCam, Seoul, South Korea) has a 
12 h operating time as compared to 8 h of the Olympus 
Endo Capsule and PillCam SB2[3]. Longer operating time 
can reduce incomplete examination and may increase 
diagnostic yield[4]. Pioche et al[3] found the MiroCam 
to have comparable efficacy to the PillCam SB2. The 
MiroCam uses human body communication for image 
transmission as opposed to radiofrequency as does 
the PillCam SB2[3]. In 2010, Given imaging introduced 
the PillCam SB2-ex which differs from its predecessor 
(PillCam SB2) in that it offers a 12 h operating time 
similar to the MiroCam. The PillCam SB2 and the 
PillCam SB2-ex have the same size and specifications 
except for the recording time[6].
 While a longer operating time may increase the 
rate of complete examinations, defined by passage of 
the capsule into the colon during its operating time, it 
is still unknown whether the additional 4 h of recording 
time will increase diagnostic yield or clinical outcomes. 
To answer these questions we investigated the 
completion rate and diagnostic yield of the new 12 h 
PillCam SB2-ex in comparison to the 8 h PillCam SB2. 
MATERIALS AND METHODS
The study was conducted at North Shore University 
Hospital after obtaining institutional review board 
approval. There was no external financial support. 
Capsules that were placed endoscopically in the 
stomach or duodenum were excluded from consi-
deration. We conducted a retrospective review of 
four hundred consecutive inpatients, 200 of whom 
had undergone 8-h PillCam SB2 from 2009 to 2011 
and 200 consecutive 12 h PillCam SB2-ex inpatient 
exams from 2011 to 2013. No inpatient studies 
using the 8-h PillCam SB2 were performed following 
the introduction of the 12 h PillCam SB2-ex in our 
practice. Demographic information, indications for 
capsule endoscopy, capsule type, study length, 
completion or incomplete exam (completion defined 
as capsule passage into the cecum during the 
recording), abnormal capsule findings divided into, 
bleeding, Arteriovenous malformation (AVM) (arterio-
venous malformation), erosive disease, polyps/
mass, and miscellaneous, timestamp of most distant 
finding, and findings beyond 8 h were recorded. All 
procedures were read by one of two experienced 
gastroenterologists. Standard protocol for inpatients 
prior to capsule endoscopy required that each patient 
receive nothing but clear liquids by mouth from at 
least noon the day before capsule ingestion, and that 
they receive nothing by mouth other than medication 
and sips of water after midnight the night before 
ingestion. There was no standard purgative bowel 
prep used at our institution before capsule ingestion. 
Two hours after capsule ingestion, the patients were 
permitted to have clears and then two hours later 
a regular diet if deemed medically appropriate by 
the gastroenterology consultant. The primary study 
endpoint was the completion rate, defined by passage 
of the capsule into the cecum during its operating 
time. The secondary endpoint was diagnostic yield, 
defined by any finding considered abnormal by the 
interpreting gastroenterologist.
Statistical analysis
For the comparison of baseline characteristics and 
Table 3  Clinically significant findings beyond the 8 h mark in 
the SB2-ex capsule group
Table 2  Characteristics and small bowel findings1 for each 
capsule group  n  (%)
Table 1  Demographics and indications for capsule endoscopy 
in each capsule group  n  (%)
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outcome variables between the PillCam SB2 and 
PillCam SB2-ex capsule groups, two sample unpaired 
t-test for continuous variables and Fischer’s exact test 
for categorical values were used. P value < 0.05 was 
considered significant. GraphPad software was used for 
all analysis. The statistical methods of this study were 
reviewed by Meredith Akerman.
RESULTS
A total of 400 cases were reviewed. The two groups 
were well matched for both age and gender as well 
as for indications for capsule endoscopy as shown in 
Table 1. There were four categories of indications for 
capsule endoscopy: anemia, obscure GI bleed, known 
history of AVM, and “other”. The “other” category 
included Crohn’s/ileitis, chronic nausea and vomiting, 
abdominal pain, diarrhea, weight loss, evaluation for 
carcinoid tumor, follow up of ileal intussusception, 
history of small bowel polyp, and history of small 
bowel obstruction.
The PillCam SB2-ex had a significantly higher 
completion rate than the PillCam SB2 (88% vs 79.5%, 
P = 0.03). The diagnostic yield was greater for PillCam 
SB2 than PillCam SB2-ex, (48.5% vs 35%, P = 0.01), 
with a greater rate of detection of AVMs (17.5% vs 
9.5%, P = 0.03). Other findings were similar between 
the two groups. The mean study lengths were 4:15:56 
and 4:51:27 for PillCam SB2 and PillCam SB2-ex, 
respectively. The most distal timestamp of a positive 
finding for the PillCam SB2-ex (15:08:22) was longer 
than that of the PillCam SB2 (7:24:21). For the PillCam 
SB2, six cases found small bowel polyps and three 
cases described a soft tissue lesion. In the PillCam 
SB2-ex, two cases identified a duodenal mass, one 
case a polypoid lesion in the jejunum, and one case a 
duodenal polyp (Table 2).
Nine cases from the total SB2-ex capsule group 
(200) had clinical significant findings beyond the 8 h 
mark. These findings are summarized in Table 3. Of 
these 9 cases, 4/70 (5.7%) of abnormal PillCam SB2-
ex small bowel findings occurred beyond 8 h.
DISCUSSION
Since the introduction in 2003 of the M2A capsule, 
capsule endoscopy has become a first line modality 
for the evaluation of obscure GI bleed[3,4]. The 
advancement of longer operating times is expected 
to offer the potential of both increasing the rate 
of completed studies and detecting more clinically 
significant findings. Our findings do confirm that the 
extra 4 h of operating time provided by the 12 h SB2-
ex resulted in a significantly higher rate of complete 
studies over the 8 h SB2 capsule for an inpatient 
population, 88% vs 79.5%, P = 0.03 respectively. Two 
retrospective studies on 8- hour capsule performed 
in Thailand and New Zealand demonstrated similar 
completion rates as our PillCam SB2 group[7,8]. 
Unfortunately the authors of the Thai study did not 
delineate whether the population of patients involved 
in the study were strictly inpatient-based, and the 
patients included in the New Zealand study were 
a mixed population of inpatients and outpatient. 
Additionally, all patients received bowel preparations, 
and some may have been given pro-motility agents. 
This highlights a difference from our own study which 
was performed exclusively in the inpatient population, 
and was done without routine use of bowel prep or 
pro-motility agents. Previously reported data have 
PillCam SB2 cases PillCam SB2-ex 
cases
P  value 
(< 0.05)
Age (mean ± SD) 70.90 ± 14.19 71.93 ± 13.80 0.46
Male 91 (45.5) 96 (48) 0.69
Obscure GI bleed    131 (65.5) 146 (73) 0.13
Anemia      47 (23.5)   36 (18) 0.22
Anemia or obscure 
GI bleed
178 (89) 182 (91) 0.62
AVM     11 (5.5)     9 (4.5) 0.82
Other     11 (5.5)     9 (4.5) 0.82
GI: Gastrointestinal; AVM: Arteriovenous malformation.
PillCam SB2 cases PillCam SB2-ex cases P  value 
(< 0.05)
Complete studies 159 (79.5) 176 (88) 0.03
Average 
completed study 
duration
4:15:56 4:51:27
Abnormal 
finding total
  97 (48.5) 70 (35) 0.01
Bleeding   21 (10.5) 20 (10) 1.00
AVM   35 (17.5)  19 (9.5) 0.03
Erosive disease 32 (16) 26 (13) 0.45
Polyp/mass (see 
text)
  9 (4.5) 4 (2) 0.26
Miscellaneous 0 1 (1) 1.00
1Some cases had multiple findings. AVM: Arteriovenous malformation.
Findings outside of the 
small bowel
Time Findings in the 
small bowel
Time
Bleeding in colon 8:59:18; 
14:09:59; 
15:08:22
Bleeding in 
duodenal bulb due 
to AVM
8:57:24
AVM in colon 8:59:34 AVM 9:34:04
Portal gastropathy 10:38:06 Denuded mucosa 
in SB
11:15:22
Jejunitis 13:02:13
AVM: Arteriovenous malformation.
Rahman M et al . Comparative efficacy of capsule systems
5545 May 14, 2015|Volume 21|Issue 18|WJG|www.wjgnet.com
found incompletion rates for 8 h capsule endoscopy 
to be as high as 25% of all cases[4,6]. These previous 
results suggest that the difference we observed was 
real, and not related to an abnormally low completion 
rate in the SB2 group. Incomplete studies may be 
due to battery/system failure before reaching the 
cecum, though this was not the case in either the 
SB2 or SB2-ex group. Other factors more commonly 
affecting completion rate such as variable bowel 
motility, delayed gastric emptying, capsule retention, 
previous SB surgery, and poor bowel cleansing[2,9] 
likely accounted for the incomplete examinations in 
both groups.
Despite the significantly higher study completion 
rate, we were unable to demonstrate a superior 
diagnostic yield for SB2-ex over SB2. In fact the 
diagnostic yield between PillCam SB2 and PillCam 
SB2-ex was 48.5% vs 35% (P value = 0.01), favoring 
improved diagnostic yield for the 8 h PillCam SB2. 
This unexpected finding would appear to challenge the 
notion that a longer operating time translates into an 
improvement in diagnostic yield. We suspect however 
that the difference in diagnostic yield found in the 
present study is related to the advancing/changing 
expertise of the interpreting gastroenterologists 
over time. As noted, the PillCam SB2 examinations 
all occurred in the years 2009 to 2011 prior to the 
PillCam SB2-ex examinations 2011 to 2013. It is 
possible that over the time period studied that the 
standards by which each of the gastroenterologists 
qualified a finding as “positive” may have changed. It 
is particularly notable that the largest classification of 
significant finding by SB2 was AVMs, found in 17.5% 
of studies, compared to 9.5% for the SB2-ex. Since 
there is no gold standard for labeling a finding as an 
AVM by capsule endoscopy it is possible that with more 
practice, the reporters’ threshold to interpret AVMs 
as a significant finding increased leading to less AVMs 
reported, and a decreased diagnostic yield overall.
Though even if we accept a similar diagnostic 
yield between the two capsule systems, there is 
still a potential for improved cost effectiveness with 
the 12 h system. Since extending the operating life 
of the capsule resulted in more complete studies, 
this would seem to offer a cost benefit by avoiding 
repeating those studies which were incomplete, by 
not prolonging the patient’s hospital admission to 
repeat incomplete studies, and by limiting the need for 
diagnostic imaging to confirm capsule passage which 
is often required when visualization of the cecum is not 
achieved during capsule recording.
While ours is the largest study to date, it is not 
the first to address diagnostic yield of an 8 h vs a 
12 h capsule[3,4]. Kim et al[4] found a nonsignificant 
increased diagnostic yield with the 12 h MiroCam 
capsule compared with the 8 h PillCam SB2 in 24 
patients (45.8% vs 41.7%), with a completion rate 
to the cecum which was higher. However, it should 
be noted that the completion was rate for standard 
PillCam SB in his study was very low at 58.3%. Pioche 
et al[3] performed a larger, multicentered, prospective, 
randomized study also comparing the diagnostic 
yield of the PillCam SB2 and MiroCam capsules in 
83 patients. In patients having both examinations 
completed, the MiroCam identified significantly more 
findings than the PillCam SB2 capsules. However, a 
more recently published study performed by Choi et 
al[10], performed in a similar fashion with 105 patients, 
was unable to show an improvement in diagnostic yield 
for the MiroCam in comparison to the PillCam SB2, 
and only showed a positive trend but not a statistical 
difference in completion rates.
In our study, significant SB findings beyond 8 h 
were identified in four cases by PillCam SB2-ex, 5.7% 
of the total “positive” studies. While this yield beyond 
8 h did not contribute to a significantly increased study 
yield overall for the 12 h system, it is notable that such 
a large percentage of significant findings occurred 
beyond the standard 8 h window.
One issue that can occur particularly often in 
hospitalized patients, is slowed or altered gastric 
motility. A potential weakness of our study was the 
lack of any control for this variable, as well as a lack 
of data regarding potential prokinetic use by the study 
population. Conversely we do know that prokinetic 
use is not routine in our institution for capsule studies. 
Given the overall demographic similarities between 
the two groups it seems unlikely that prokinetic use 
effected the study results if it was in fact utilized. 
In two of the eight cases mentioned above, despite 
the capsule retention in the stomach for a portion of 
time equivalent to the complete battery life of the 
PillCam-SB2, the additional battery life of the PillCam 
SB2-EX allowed the capsule enough time to locate 
a finding of clinical interest. Prokinetics have been 
used to shorten small bowel transit time and possibly 
improve completion rates[11]. In a meta-analysis by 
Koulaouzidis et al[11], a statistically higher completion 
rate was found in patient who ingested the capsule 
with metoclopramide vs control [OR (95%CI): 
2.8 (1.35-3.21)]. In addition, a prospective study 
comparing metoclopramide ingestion prior to capsule 
endoscopy vs control found statistically significant 
higher completion rates in the former group (97% vs 
76%)[12]. These studies were both performed using the 
8-h capsules.
Additionally, bowel preparation can affect the 
degree of visualization of the small bowel[13]. Currently, 
European guidelines advocate the use of a PEG 
preparation for capsule endoscopy[14]. It has been 
shown that using a bowel prep in addition to a 
prokinetic agent can increase completion rate, as 
shown in a meta-analysis published by Koulaouzidis 
et al[11]. In Pioche’s study, polyethylene glycol (PEG) 
was used for bowel cleanliness in patients receiving 
the MiroCam or the PillCam SB2[3]. The diagnostic yield 
was higher for the MiroCam when compared to PillCam 
SB2. Our institution capsule protocol required each 
Rahman M et al . Comparative efficacy of capsule systems
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patient to have nothing but clear liquids from noon the 
day before the examination and to receive “nothing by 
mouth” the night prior to capsule ingestion. While no 
specific purgative bowel preparation was required for 
capsule examination, we know from standard practice 
in the institution that many of these patients had their 
study performed soon after a negative colonoscopy 
which itself involved a bowel cleanse. As it was not 
standard to address bowel purgative use prior to 
capsule study in the capsule reports, it is unknown how 
purgative use may have been a potential confounding 
factor.
An additional limitation of our study is its non-
randomized nature, notably with the pre-procedure 
indication of obscure GI bleeding differing between the 
two groups. When including both obscure GI bleed and 
anemia together as an indication, there was no longer 
a statistical difference between the study groups. 
There was also no control for the timing of capsule 
endoscopy in these cases of obscure GI bleeding. Prior 
studies have shown that capsule endoscopy performed 
within the first few days of obscure GI bleed increases 
the diagnostic yield[15-17].
In our study, obscure GI bleeding was the major 
indication for both PillCam SB2 (65.5%) and PillCam 
SB2-ex (73%) capsule studies. In the PillCam SB2-ex 
group, the most common findings were active small 
bowel bleeding, erosive disease, and AVM with rates 
of 10%, 13%, and 9.5%, respectively. Our findings 
are similar to prior reports. In a large meta-analysis 
involving 22840 capsule endoscopies, AVM was the 
most common diagnosis for obscure GI bleed followed 
by small bowel inflammation/ulcers[9].
In conclusion we have demonstrated superior 
completion rates for the PillCam SB2-ex 12 h capsule 
as compared to the 8 h PillCam SB2. We were unable 
to demonstrate a superior overall diagnostic yield of 
the 12 h system despite a notable number of clinically 
significant findings detected beyond the 8 h mark, 
including active bleeding, in the SB2-ex group. Further 
prospective randomized studies will be needed to 
confirm the advantage of PillCam SB2-ex over PillCam 
SB2.
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Capsule endoscopy systems are being created with longer operating time. The 
current research hotspot is to evaluate whether these longer operating capsules 
truly have better diagnostic yield.
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diagnostic yield compared to the PillCam SB2.
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